Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

Sponsor
PeriPharm
Study ID
NCT06311864
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.

Key Dates

Start date
Jun 20, 2024
Status verified
May 2026
Primary completion
May 19, 2026
Completion
May 19, 2026

Study Design

Enrollment
90 participants (actual)

Arms

  • Arm: daridorexant
    Patients who have been newly prescribed oral tablets of daridorexant 50 mg to treat their insomnia

Primary Outcome Measure

Change from Baseline in Quality of Life [ Time Frame: Month 1, Month 2, Month 3 ]

Related Studies